Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.05 USD | -0.97% | -8.47% | -47.41% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- The company has insufficient levels of profitability.
- For the last few months, analysts have been revising downwards their earnings forecast.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-46.90% | 20.52M | B- | ||
+1.77% | 42.86B | B | ||
+46.00% | 41.36B | A | ||
+12.24% | 42.74B | B- | ||
-8.83% | 27.68B | C | ||
+7.44% | 25.15B | B- | ||
-23.01% | 18.63B | B | ||
+30.56% | 12.37B | C+ | ||
-1.82% | 11.92B | C+ | ||
+8.35% | 11.21B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- MEIP Stock
- Ratings MEI Pharma, Inc.